We reported that silencing the WNT receptor ROR2 results in protection from cartilage breakdown and rapid pain relief in a murine model of osteoarthritis and in chondrogenesis in vitro and in vivo with human osteoarthritic chondrocytes (Thorup et al. Sci Transl Med 2020). We have now developed a recombinant molecule that that blocks ROR2 and is chondrogenic in vitro. With this application we want to further optimise this molecule to extend its half-life in vivo and we aim at providing efficacy data in animal models of osteoarthritis.
Applications should be sent directly to QMUL admissions via this link (choosing the category: PhD Full-time William Harvey Research Institute (non-clinical) Semester 1 (September Start)):
The closing date for applications is Wednesday 20th July 2022, interviews will be thereafter. Start date is 1st September 2022